TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Saved in:
| Title: | TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. |
|---|---|
| Authors: | Erazo T; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Evans CM; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pharmacology, Weill Cornell School of Medical Sciences, New York, NY, USA., Zakheim D; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Chu EL; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Refermat AY; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Asgari Z; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yang X; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Da Silva Ferreira M; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mehta S; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Russo MV; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Knezevic A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zhang XP; Epigenetics Research Unit, GlaxoSmithKline, Collegeville, PA, 19426, USA., Chen Z; Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY, 10021, USA., Fennell M; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Garippa R; Gene Editing and Screening Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Seshan V; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Barbash O; Epigenetics Research Unit, GlaxoSmithKline, Collegeville, PA, 19426, USA., Batlevi CL; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Leslie CS; Computational Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Melnick AM; Division of Hematology and Medical Oncology, Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA., Younes A; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. anas.younes@astrazeneca.com., Kharas MG; Molecular Pharmacology Program, Experimental Therapeutics Center and Center for Stem Cell Biology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kharasm@mskcc.org. |
| Source: | Nature communications [Nat Commun] 2022 Sep 27; Vol. 13 (1), pp. 5676. Date of Electronic Publication: 2022 Sep 27. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
